(TheConservativeTimes.org) – The makers of Ozempic and Wegovy are working on another daily weight loss pill, and they have just shared their results from an early-stage trial. Novo Nordisk released data recently that showed patients taking its new medication, a pill called amycretin, lost up to thirteen percent of their body weight after just twelve weeks.
This is data from Phase I of the study, and it was presented at the European Association for the Study of Diabetes meeting held in Madrid.
This daily pill has the potential to mark a huge turning point in the fight against obesity, which affects over forty percent of people in the United States, according to the Centers for Disease Control and Prevention.
The study was small and only looked at a total of one hundred and twenty-four participants. Researchers found that those with the highest dose of the drug lost about thirteen percent of their body weight compared to a placebo group which lost just one percent of their body weight over the same period of time.
Participants that took amycretin experienced moderate side effects of nausea and vomiting, but no dangerous side effects were reported. It could take several years before this drug hits the market as they just began testing it.
Dr. Leah Croll, a neurologist in Philadelphia, said, “The journey from lab to your local pharmacy shelf is a years-long journey, typically, for these drugs.”
She continued, “It involves multiple rounds of clinical trials, big trials that may take years to execute, so I’d say we’re looking at least a couple of years.”
Copyright 2024, TheConservativeTimes.org
